Vaginal Gel

Description
Gel for the prevention and adjuvant treatment of lesions caused by papillomavirus (HPV).
- Creates a defensive barrier that prevents the risk of HPV integration and the formation of new lesions.
- Adjuvant in the re-epithelization of existing lesions.
- Stimulates the regeneration of the vaginal microbiota.
Papilocare is indicated for:
- control and help re-epithelialize the cervical transformation area to prevent the risk of lesions (LSIL) caused by HPV;
- adjuvant treatment of intraepithelial lesions caused by HPV;
- repair and help re-epithelialize lesions of the cervico-vaginal mucosa;
- treat dryness of the cervico-vaginal mucosa;
- rebalance the vaginal microbiota;
- improve vaginal health;
- create the conditions for rapid healing of lesions caused by rubbing due to burning or itching;
- form a protective film that quickly reduces discomfort, creating the right conditions to promote the natural healing process.
The main components of the formulation are:
- substances that allow the formation of a mucoadhesive gel on the cervical-vaginal mucosa, creating a protective film on it which favors the barrier action of the product;
- hyaluronic acid niosomes, with a hydrating action on the tissues, which help preserve their elasticity;
- beta-glucan niosomes: thanks to their antioxidant properties, they maintain the structure and natural functionality of the skin and mucous membranes;
- Centella Asiatica phytosomes, with a repairing action on damaged mucous membranes;
- Coriolus versicolor extract, with a re-epitalising and repairing action on cervico-vaginal lesions and micro-lesions;
- neem extract, with emollient properties that promote the natural healing process;
- BioEcolia, prebiotic that stimulates the growth of beneficial bacterial flora and balances the microbiota in the cervico-vaginal area;
- aloe vera extract with hydrating, re-epitalising and repairing action on the cervical-vaginal area.
The use of Papilocare is recommended for papillomavirus (HPV) positive (adult) women, regardless of the presence of lesions caused by the virus (ASCUS orLSIL).

Instructions for use
The duration of treatment is 6 months, with the possibility of further extending the period based on the medical prescription. It is important to complete the entire course of treatment to achieve the expected results.
It is recommended to start treatment after the menstrual cycle.
First month: apply one cannula per day for 21 consecutive days, then suspend treatment for the following 7 days.
Subsequent months (from the second to the sixth): apply a cannula every other day for 21 days.
Suspension of treatment with Papilocare during the menstrual cycle is recommended only for the convenience of patients; in fact, there are no clinical incompatibilities.
Apply preferably before sleeping.
It is compatible with the use of a condom.
Discard any cannula that is open or broken. The cannula is designed to facilitate the administration of the product. Introduce the cannula into the vagina and apply pressure to release the contents. Then extract the cannula from the vagina, keeping it pressed so that it does not re-aspirate the dispensed product.
There may be some gel left inside the cannula; this does not mean that a lower dose than the recommended one has been delivered since the cannula releases the quantity sufficient to cover the cervico-vaginal mucosa (3 ml). Discard the cannula once used. Do not reuse an already used cannula